Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149734 · ClinicalTrials.gov registry record · Phase 3
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00149734: Completed Phase 3 study of Schizophrenia, sponsored by University of Colorado, Denver.
NCT00149734 is a Phase 3 study of Schizophrenia that has completed, run by University of Colorado, Denver. The registered enrollment target is 8 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00149734, a Phase 3 study of Schizophrenia, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
Primary Outcome
P50 Sensory Gating as measured by evoked potentials (response to stimuli, in this case, clicking sounds).The P50 potential was identified and measured using a computer algorithm. The amplitude of the P50 test wave was divided by the amplitude of the P50 conditioning wave, expressed as a percentage: the P50 ratio. Lower P50 ratios represent better outcomes.
Conditions Studied
Interventions
- DRUG Ondansetron followed by placebo
- DRUG Placebo followed by Ondansetron
Study Locations (1)
Colorado
- Denver VAMC - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00149734 record still lists
NCT00149734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron followed by placebo is the first listed.
NCT00149734 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00149734 about?
NCT00149734 is a clinical study titled "Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia". This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
What is the current status of trial NCT00149734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2005-01. Estimated completion is 2010-05.
What conditions does trial NCT00149734 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00149734?
The interventions under investigation include: Ondansetron followed by placebo (DRUG), Placebo followed by Ondansetron (DRUG).
Who is sponsoring clinical trial NCT00149734?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00149734 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00149734's enrollment target sits among peer trials
8 314th of 315 higher than 1 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia